Shares of NuVasive are down around 33% today after the company preannounced third-quarter revenues below their guided range. The company now expects $147 million in third-quarter revenues, a sharp deceleration in growth and enough to frighten shareholders of the producer of spinal surgery products. There's plenty of reason to be worried, too, after management provided numerous reasons behind the decline that could have longer-term implications. Follow along in the video below as Fool.com health care bureau chief Brenton Flynn runs through the NuVasive news in more detail.
Many medical devices, like all technology, are subject to becoming obsolete because of continual innovation. It's a risk worth taking in some instances, but if you're looking for something different, you should check out our new free report, "The Motley Fool's Top Stock for 2012." In it, our chief investment officer identifies his favorite company for the year. To access the report before the rest of the market catches on, click here -- it's absolutely free.
Brenton Flynn has no positions in the stocks mentioned above. The Motley Fool owns shares of Johnson & Johnson and Medtronic. Motley Fool newsletter services recommend Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.